Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02102711|
Recruitment Status : Completed
First Posted : April 3, 2014
Last Update Posted : March 22, 2019
Vitamin A is essential for optimal growth, and development. In the newborn, especially if preterm, it is necessary for the cellular differentiation, for the health of the anterior eye, it is a constituent of visual pigment, and it is essential for surfactant synthesis. Immune response Vitamin A supplementation demonstrated to reduces infancy mortality, but very low (<1500g birth weight) and extremely low (<1000g birth weight) preterm infants are born with low body stores of vitamin A and are at high risk of vitamin A deficiency. Nevertheless, optimal vitamin A supplementation for these infants is not clearly defined, despite evidence of benefit of an early supplementation.
Prematurity is associate to the risk for bronchopulmonary dysplasia (BPD) which is a disease marked by respiratory compromise associated with high mortality and severe long-term morbidity, as well as prematurity is associate to the risk for retinopathy, a pathology that may be related to less rhodopsin quantity which seem dependent on vitamin A concentration. Vitamin A can be given enterally, intramuscularly, or intravenously. Recently an oral administration as drops is available resulting particularly convenient avoiding the pain associated with repetitive intramuscular injections, or the discomfort of parenteral administration. Studies of vitamin A in the infant population suggest that plasma retinol concentrations >0.7 µM/L indicate vitamin A sufficiency, nevertheless preterm infants have lower concentration and concentration < 0.35 µM/L are very dangerous. Vitamin A deficiency at this level may constitute a problem for preterm newborn, resulting for example, in histological alterations in the respiratory epithelium leading to chronic lung disease, retinopathy of prematurity, patency of the ductus arteriosis, and immune competence deficiency.
The aim of the present study is to verify efficacy and tolerability of a new oral administration of vitamin A as drops, 3000 IU/kg/die for 4 weeks, in infants < 1500g weight at birth, verifying the competence of the supplementation reaching ideal blood concentration (≥0.7 µM/L) and relating the blood achieved concentrations of vitamin A to the outcome in typical pathologies, as BPD and ROP. Not treated group of matched newborn infants is the controlarm.
|Condition or disease||Intervention/treatment||Phase|
|Bronchopulmonary Dysplasia Retinopathy of Prematurity||Dietary Supplement: Vitamin A oral drops||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g Efficacy and Tolerability in the Prevention of Bronchopulmonary Dysplasia (BDP) and Retinopathy of the Prematurity (ROP)|
|Actual Study Start Date :||April 2014|
|Actual Primary Completion Date :||April 2015|
|Actual Study Completion Date :||April 2016|
Experimental: vitaminA drops
3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
Dietary Supplement: Vitamin A oral drops
Other Name: VISPO, BIOTRADING Pharma
No Intervention: control
Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
- Vitamin A blood concentration (µM/L) [ Time Frame: participants will be followed for the duration of Vitamin A oral administration, an expected average of 4 weeks ]Vitamin A functional concentration
- number of bronchopulmonary dysplasia and of retinopathy of prematurity [ Time Frame: 1 year ]number of events
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02102711
|IRCCS Policlinico S. Matteo|
|Pavia, PV, Italy, 27100|
|IRCCS Policlinico S.Matteo; Neonatal Intensive Care Unit|
|Pavia, Italy, 27100|
|Study Director:||Mauro Stronati, MD||IRCCS Policlinico S. Matteo, Pavia, Italy|